sur ONXEO (EPA:ALONX)
Valerio Therapeutics Welcomes Professor Eric Vivier to its Board of Directors
Valerio Therapeutics announces the appointment of Professor Eric Vivier as an observer to its Board of Directors. Eric Vivier is recognized for his contributions to immunology research. He is a professor at AP-HM (Assistance Publique - Hôpitaux de Marseille) and École Polytechnique, and heads a research group at the Marseille-Luminy Immunology Center.
His academic career and distinctions, including the ERC award, attest to his influence in the field. He was an active member of the National Academy of Medicine and has been listed among the world's most cited researchers for eleven years.
Julien Miara, CEO of Valerio Therapeutics, expressed his enthusiasm for this collaboration, which is expected to enrich the company's oncology strategies. Particular emphasis will be placed on developing new approaches for the treatment of solid tumors, where significant unmet medical needs remain.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ONXEO